Leslie Ross
Family · Glen Rose, TXNPI 1447640669
Payments from drug & device makers
Across 255 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$561
- Novo Nordisk$289
- Exact Sciences$241
- Supernus Pharmaceuticals, Inc.$212
- Otsuka America Pharmaceutical, Inc.$203
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,46599%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $1,267 |
| Amgen | 29 | $561 |
| Novo Nordisk | 18 | $289 |
| Exact Sciences | 12 | $241 |
| Supernus Pharmaceuticals, Inc. | 1 | $212 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| AstraZeneca | 11 | $189 |
| Lilly USA, LLC | 11 | $175 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $131 |
| Axsome Therapeutics, Inc. | 6 | $119 |
| Seagen Inc. | 5 | $101 |
| Pfizer | 4 | $81 |
| Antares Pharma, Inc. | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 5 | $69 |
| Abbott | 4 | $67 |
| Dexcom, Inc. | 3 | $62 |
| Astellas Pharma US Inc | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Bayer | 3 | $48 |
| Ardelyx, Inc. | 2 | $44 |
| Alfasigma USA, Inc. | 3 | $42 |
| Eisai Inc. | 2 | $39 |
| Currax Pharmaceuticals LLC | 2 | $37 |
| Genentech USA, Inc. | 5 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| IBSA Pharma Inc. | 1 | $25 |
| Mycovia Pharmaceuticals, Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,490 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $116,471 |
| OzempicSemaglutide | 25 | $34,454 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $22,095 |
| EliquisApixaban | 33 | $21,907 |
| VraylarCariprazine Hcl | 11 | $15,654 |
| TrulicityDulaglutide | 12 | $11,322 |
| JardianceEmpagliflozin | 17 | $10,037 |
| FarxigaDapagliflozin Propanediol | 15 | $9,505 |
| JentaduetoLinagliptin/Metformin Hcl | 11 | $5,813 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,258 |
| Levothyroxine Sodium | 243 | $1,784 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $1,776 |
| ProgesteroneProgesterone, Micronized | 38 | $1,567 |
| Armour ThyroidThyroid,pork | 14 | $1,432 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $1,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $175 | $127,79391 claims |
| Novo NordiskOzempic | $289 | $34,45425 claims |
| PfizerEliquis | $81 | $21,90733 claims |
| AbbVieVraylar, Armour Thyroid | $1,267 | $17,08725 claims |
| AstraZenecaFarxiga | $189 | $9,50515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Glen Rose
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.